A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy
Open Access
- 27 May 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1857016
Abstract
Introduction: Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are immune-mediated inflammatory neuropathies characterized by T cell– and/or autoantibody-driven injury to peripheral nerves. Although intravenous immunoglobulin (IVIg) is effective in both conditions, its use is limited by high dosing requirements, supply constraints, and manufacturing complexity. NVG-2089 is a recombinant IgG1 Fc-domain protein engineered to selectively agonize type II Fc receptors, promoting anti-inflammatory signaling through expansion of regulatory T cells (Tregs) and upregulation of the inhibitory Fcγ receptor FcγRIIB. Its efficacy in immune complex–mediated disease and T cell–driven neuroinflammation prompted evaluation of its therapeutic potential in an animal model of inflammatory demyelinating neuropathy. Methods: We conducted a randomized, blinded preclinical study in the spontaneous autoimmune peripheral polyneuropathy model, a well-established murine model of inflammatory demyelinating neuropathy. Animals were treated with NVG-2089, high-dose IVIg, or vehicle. Outcomes included behavioral performance, nerve electrophysiology, peripheral nerve morphometrics, immunohistochemistry, and flow cytometric immunophenotyping. Results: Both NVG-2089 and IVIg stabilized motor and sensory performance, preserved compound muscle action potential (CMAP) amplitudes, and attenuated demyelination-associated prolongation of distal latency and CMAP duration. Morphometric analyses demonstrated preservation of myelinated fiber density and normalization of g-ratio distributions in both treatment groups. Immunophenotyping indicated an expansion of functionally activated CD25 + CD39 + Tregs in the spleen, along with increased FcγRIIB expression on B cells, monocytes, and dendritic cells across systemic and nerve-associated compartments, consistent with engagement of shared anti-inflammatory pathways. Conclusions: NVG-2089 demonstrated robust neuroprotective efficacy comparable to IVIg while requiring a substantially lower protein dose. These findings support NVG-2089 as a promising, dose-efficient alternative to IVIg for the treatment of inflammatory demyelinating neuropathies, including GBS and CIDP.Keywords
This publication has 80 references indexed in Scilit:
- Intravenous immunoglobulin and plasma exchange prescribing patterns for Guillain‐Barre Syndrome in the United States—2001 to 2018Muscle & Nerve, 2024
- Rejuvenating fecal microbiota transplant enhances peripheral nerve repair in aged mice by modulating endoneurial inflammationExperimental Neurology, 2024
- Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg TherapyNeurotherapeutics, 2021
- Monocarboxylate transporter 1 in Schwann cells contributes to maintenance of sensory nerve myelination during agingGlia, 2019
- Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injuryExperimental Neurology, 2016
- Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic interventionActa Neuropathologica, 2015
- IVIG Treatment and Prognosis in Guillain–Barré SyndromeJournal of Clinical Immunology, 2010
- Biphasic form of experimental autoimmune neuritis in dark agouti rats and its oral therapy by antigen‐specific tolerizationJournal of Neuroscience Research, 2003
- Axonal Guillain-Barr syndrome: Relation to anti-ganglioside antibodies andCampylobacter jejuni infection in JapanAnnals of Neurology, 2000
- Pathology of the Guillain-Barr syndromeAnnals of Neurology, 1981